AddedRisk Factors
Furthermore, professional societies, practice management groups, private health and science foundations and other organizations publish guidelines or recommendations to the healthcare and patient communities relating to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients and healthcare providers could result in decreased use of our products.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
If we fail to obtain or maintain regulatory exclusivity for our product candidates, our business may be materially harmed.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
We may be unable to obtain, or may not be able to maintain, regulatory exclusivity for our products or product candidates, including exclusivity under the Hatch-Waxman Act, orphan drug exclusivity, Generating Antibiotic Incentives Now Act exclusivity, or pediatric exclusivity. Even if granted, such exclusivity may be limited in scope or duration and may not prevent competitors from developing or marketing competing products. For example, while BRINSUPRI is eligible for five-year new chemical entity exclusivity, which should block submission of an Abbreviated New Drug Application (ANDA) or 505(b)(2) with the same active moiety for five years (or four years, if a paragraph IV certification of patent invalidity, unenforceability, or non-infringement is filed), if another sponsor submits a 505(b)(1) application for a drug containing the same active moiety, BRINSUPRI’s regulatory exclusivity would not block submission of that product. The loss or expiration of any exclusivity period could allow competitors to introduce generic or other competing products, which may significantly reduce our revenues and adversely affect our business, financial condition, and results of operations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
Generic competition following the expiration or loss of exclusivity may significantly reduce our revenues.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedRisk Factors
•We may not be successful in clinical trials or in obtaining regulatory approvals required to expand the indications for ARIKAYCE, which may materially adversely affect our prospects and the value of our common stock.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Failure to obtain or maintain regulatory approval or clearance of our product devices, including Lamira, as a delivery system for ARIKAYCE, and the dry powder delivery system for TPIP, could materially harm our business.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our long-term viability and growth depend on the continued successful commercialization of ARIKAYCE, our only approved product. ARIKAYCE was approved in the US for the treatment of MAC lung disease as part of a combination
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
used to carry the genetic material, which could adversely affect our ability to obtain and maintain regulatory approvals for and commercialize any gene therapy products we may develop.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
In January 2024, the US House of Representatives introduced the BIOSECURE Act (H.R. 7085) and the Senate advanced a substantially similar bill (S.3558), which legislation, if passed and enacted into law, would potentially restrict our ability to utilize certain products and services from, or otherwise collaborate with, any "biotechnology company of concern,” in the performance of a government contract or subcontract. Although the House version of the bill passed on September 9, 2024, the legislation ultimately did not pass before the end of the last session of Congress. It is possible that the BIOSECURE Act could be raised again in some form in this new and current session of Congress, either as a standalone bill or as part of broader legislation, and focus on these issues is expected to continue. We do business with companies in China and it is possible some of our contractual counterparties could be impacted by this legislation.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Compounds, products or
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
business in the form of higher costs for labor and materials, possible reductions in pharmaceutical industry-wide spending on research and development and acquisitions and higher costs of capital.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical, scientific and factual questions, and our success depends in large part on our ability to protect our
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
change, or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, including our NDA submission for brensocatib, which could have a material adverse effect on our business.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
In May 2021, we completed an underwritten offering of 0.75% convertible senior notes due in 2028 (the 2028 Convertible Notes). The 2028 Convertible Notes may be convertible into common stock at an initial conversion rate of 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes. We sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters’ option to purchase additional 2028 Convertible Notes, resulting in net proceeds of approximately $559.3 million. Holders of the 2028 Convertible Notes may convert their 2028 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 1, 2028, only under certain circumstances, which circumstances have existed each quarter since the third quarter of 2024. On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2028 Convertible Notes at any time. Upon conversion of the 2028 Convertible Notes, we may deliver cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•We may elect to make cash payments upon conversion of the 2028 Convertible Notes, which would reduce our available cash.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
conversion of the 2028 Convertible Notes could be used to satisfy short positions, or the anticipated conversion of the 2028 Convertible Notes into shares of our common stock could depress the price of our common stock. The future issuance of any additional shares of common stock will dilute our current shareholders and may create downward pressure on the value of our shares. The potential for the issuance of a significant amount of our common stock pursuant to the 2028 Convertible Notes could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, could also hinder our ability to raise additional equity capital at a time and price that we deem reasonable or appropriate.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Additionally, a substantial portion of our commercial supply of ARIKAYCE is currently manufactured in Canada and, if approved, we expect that Canada, our commercial supply of brensocatib will BRINSUPRI is also be manufactured in Canada. Canada, and our supply of treprostinil palmitil, the treprostinil prodrug present in TPIP, is currently dependent on a single supplier located in Taiwan.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have invested and continue to invest significant efforts and financial resources in the commercialization of ARIKAYCE, ARIKAYCE and our ability to continue to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE from the FDA by conducting an appropriate confirmatory post-marketing study. BRINSUPRI.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if brensocatib or another any of our product candidate candidates is approved, or if ARIKAYCE is approved outside of the US, Europe and Japan, or if BRINSUPRI is approved outside of the US and the EU, regulators may limit the indications for which the product may be marketed, require extensive warnings on the product labeling labeling, require other burdensome risk mitigation measures, such as distribution restrictions, or require expensive and time-consuming additional clinical trials or reporting as conditions of approval.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have obtained accelerated approval for ARIKAYCE in the US, approval for ARIKAYCE in Europe and Japan and approval for BRINSUPRI in the US and approval in the EU and Japan, EU, seeking regulatory approvals for brensocatib and any future regulatory approvals for our other product candidates candidates, as well as approval for ARIKAYCE in front-line NTM lung disease or for ARIKAYCE or BRINSUPRI in other jurisdictions presents significant obstacles.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may not be able to obtain regulatory approvals for brensocatib, or for our other product candidates and we may not be able to receive approval for ARIKAYCE in front-line NTM lung disease disease, for ARIKAYCE or BRINSUPRI in new markets. additional markets or for our product candidates.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
At this time, while we believe that ARIKAYCE will be excluded from negotiation due to its orphan drug designation, we We cannot predict other potential implications the IRA provisions will have on our business or the pricing of brensocatib or TPIP, our product candidates, if approved, or any approved.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors’ products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could any claims that gene therapy is unsafe, or gene therapy being unable to gain the acceptance of the public or the medical community may further adversely impact our product candidates in the form of increased government regulation, unfavorable public perception, lack of physician adoption, the need for additional testing or monitoring, potential regulatory delays, stricter labeling requirements, and a decrease in demand.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to generate revenue depends on the success of commercial sales of ARIKAYCE; ARIKAYCE and BRINSUPRI; however, we do not anticipate our revenue from achieving profitability for the sale of ARIKAYCE will be sufficient for us to become profitable without reductions in our operating expenses. foreseeable future.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Despite receiving FDA, EC and Japan's Japan’s MHLW approval of ARIKAYCE, ARIKAYCE and FDA and EC approval of BRINSUPRI for the specified indications, market acceptance may vary among physicians, patients, third-party payors or others in the healthcare community. community and is dependent on a number of factors, including the following:
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial for ARIKAYCE in patients with MAC lung disease, which we commenced in the fourth quarter of 2020, and submit periodic reports on the progress of this clinical trial.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material, which may adversely affect our ability to obtain and maintain regulatory approvals for and commercialize any gene therapy products we may develop.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP, BRINSUPRI, or our other product candidates are overstated or data we have used to identify physicians is prove inaccurate, our ability to earn generate revenue to support our business could may be materially adversely affected.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Failure to obtain or maintain regulatory approval or clearance of any of our devices or drug-device combination products could may materially harm our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we fail to comply with these laws, we could may be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could may adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Data submitted to regulators are subject to varying interpretations that could may delay, limit or prevent regulatory agency approval.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Resolving such delays could may force us or third parties to incur significant costs, limit our allowed activities or the allowed activities of third parties, diminish any competitive advantages that we or our third parties may attain or adversely affect our ability to receive royalties, any of which could may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Based on feedback and in alignment with the FDA, we have determined that the primary endpoint for the ENCORE trial will would include eight questions from the QOL-B respiratory domain PRO.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Both of these risks, in turn, could may affect our ability to successfully commercialize ARIKAYCE and BRINSUPRI and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In either circumstance, even if we obtain regulatory approval, we may be unable to commercialize the product on a scale sufficient to generate significant revenue from such product candidates, which could may have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, may be interpreted differently if additional data are disclosed, and are subject to audit and verification procedures that could may result in material changes in the final data.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Failure to obtain or maintain regulatory approval or clearance of any of our devices or drug-device combination products could may materially harm our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These risks could may materially harm our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could may result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, with respect to our product candidates, our manufacturers and their facilities are subject to pre-approval cGMP inspection by the FDA and other regulatory authorities, and the findings of the cGMP inspection could may result in a failure to obtain, or a delay in obtaining, regulatory approval for future product candidates.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
All product costs for BRINSUPRI incurred prior to FDA approval on August 12, 2025 were expensed as R&D expenses. We expect our cost of product revenues (excluding amortization of intangible assets) to benefit during 2026 and beyond, as we sell through inventory that was expensed prior to FDA approval of BRINSUPRI.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we acquired the global rights to OpSCF (renamed INS1148) from Opsidio. The Opsidio shareholders may become entitled to receive contingent payments up to an aggregate of $382 million in cash upon the achievement of certain development, regulatory and sales milestones, as well as earnout payments based upon a low to mid single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In June 2023, we acquired all of the issued and outstanding share capital of Adrestia, a privately held, pre-clinical stage company. Adrestia's former shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In January 2023, we acquired Vertuis, a privately held, pre-clinical stage company. The Company is obligated to pay the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
the option to negotiate a future agreement with us for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
Our operating results for the year ended December 31, 2024, included the following:
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•Product revenues, net, increased $58.5 million, or 19.2%, as compared to the prior year as a result of the growth in ARIKAYCE sales;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The cost of product revenues (excluding amortization of intangibles) increased $20.2 million, or 30.8%, as compared to the prior year primarily as a result of the growth in ARIKAYCE sales;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
In May 2021, we completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes pursuant to an indenture between the Company and Wells Fargo Bank, National Association, as trustee (the Indenture). Net proceeds from the offering, after deducting underwriting discounts and offering expenses of $15.7 million, were $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes are convertible into common stock of the Company under certain circumstances described in the Indenture. On July 1, 2024 and October 1, 2024, the 2028 Convertible Notes became convertible, through the end of the third quarter of 2024 and fourth quarter of 2024, respectively, by the holders of such notes due to the satisfaction of the Stock Price Convertibility Trigger applicable to such notes. The current conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). We have elected to settle any conversions of the 2028 Convertible Notes in shares of common stock. For more information, see Note 10 - Debt in our notes to the consolidated financial statements.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We have a licensing agreement with PARI for the use of optimized Lamira for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, we have rights under several US and
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
In 2004 and 2009, we entered into research funding agreements with CFFT whereby we received $1.7 million and $2.2 million, respectively, in research funding for the development of ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, we owe milestone payments to CFFT of $13.4 million in the aggregate payable through 2025, of which $10.4 million has been paid as of December 31, 2024. Furthermore, if certain global sales milestones were met within five years of the commercialization of ARIKAYCE, we would have owed up to an additional $3.9 million. Through December 31, 2024, we have met and paid $1.7 million of these additional global sales milestone payments.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The timing and cost of our current and future clinical trials of ARIKAYCE for the treatment of patients with NTM lung infections, including the ENCORE trial;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to the $65.8 $76.7 million increase in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount, a $21.2 $45.5 million increase in manufacturing expense, and the $40.0 million up-front cash consideration in connection with the acquisition of INS1148, partially offset by the $12.5 million AstraZeneca milestone upon our release of an official public statement that we intended to file an NDA for brensocatib, and a $9.5 million increase brensocatib in regulatory, quality assurance, and medical affairs expense, partially offset by the $86.7 million non-cash asset acquisition cost of Adrestia and Vertuis in 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We may need to raise additional capital to fund our operations, including the development and potential commercialization of brensocatib, continued commercialization of ARIKAYCE, current and future clinical trials related to ARIKAYCE, development of TPIP, our future product candidates, and the potential development, acquisition, to develop, acquire, in-license or co-promotion of co-promote other products or product candidates, including those that address orphan or serious diseases. diseases with significant unmet need.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The net Net cash used in operating activities during was $935.0 million and $683.9 million for the years ended December 31, 2024 2025 and 2023 2024, respectively, which was primarily for the driven by commercial, clinical, and manufacturing activities related to ARIKAYCE, commercial and commercial readiness activities for BRINSUPRI, as well as other SG&A expenses and expenses, clinical trial expenses related to brensocatib and TPIP. TPIP, and the $40.0 million acquisition of INS1148.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital to fund future development of our product candidates, and may do so through equity to develop, acquire, in-license or debt financing(s), strategic transactions co-promote other products or otherwise. product candidates, including those that address serious diseases with significant unmet need.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be expenses related to our commercialization efforts for ARIKAYCE and BRINSUPRI and development costs for our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and clinical-stage assets, and, to a lesser extent, expenses related to the clinical development of TPIP and INS1201, and our pre-clinical research programs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cash used for investing activities for During the year ended December 31, 2024 as compared to 2023 is due to the 2024, net cash used in investing activities consisted primarily of purchases of marketable securities, partially offset by maturity maturities of certain marketable securities.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of product revenues (excluding amortization of intangibles) were $122.9 million for the year ended December 31, 2025 as compared to $85.7 million for the year ended December 31, 2024 as compared to $65.6 million for the year ended December 31, 2023, 2024, an increase of $20.2 $37.2 million, or 30.8%. 43.4%.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
R&D expenses were $771.1 million for the year ended December 31, 2025 as compared to $598.4 million for the year ended December 31, 2024 as compared to $571.0 million for the year ended December 31, 2023, 2024, an increase of $27.4 $172.7 million, or 4.8%. 28.9%.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We had cash and cash equivalents of $510.4 million as of December 31, 2025 as compared with $555.0 million as of December 31, 2024 as compared with $482.4 million as of December 31, 2023, an increase of $72.7 million. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, as of December 31, 2025, we had marketable securities of $919.6 million as compared to $878.8 million as of December 31, 2024 as compared to $298.1 million as of December 31, 2023, an increase of $580.7 million. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense was $83.8 million for the year ended December 31, 2025 as compared to $84.9 million for the year ended December 31, 2024 as compared to $81.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates. rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The change is related to the fair value of the potential future consideration to be paid to former equityholders of the certain businesses we have acquired.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
Upon regulatory approval by the FDA of an NDA, we will owe paid AstraZeneca an additional $30.0 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
We are not obligated to make any additional milestone payments for any additional indications.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new